FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554594679> ?p ?o ?g. }

• W2554594679 abstract "Abstract Background Current prognostic model for multiple myeloma (MM) is based on International Staging System (ISS) and presence of specific chromosomal abnormalities (CAs), especially by fluorescence in situ hybridization (FISH) analysis. MicroRNAs (miRNAs) play important roles in the development and progression in multiple myeloma (MM). Previously, we have described that plasma miRNA profiling has showed considerably lower plasma miR-92a levels in newly diagnosed MM patients (Yoshizawa et al. Blood Cancer Journal 2(1):e53, 2012). The aim of this study was to investigate the impact of plasma miR-92a levels to CAs and to prognosis in patients with newly diagnosed MM. Patients and methods From April 2004 to December 2012, 60 patients with newly diagnosed symptomatic MM (median age, 66 years; range, 34-93 years) were included in this study. We measured plasma miR-92a values (miR-92a/miR-638) by qRT-PCR. They were divided into high-risk and standard-risk by using FISH and conventional cytogenetic studies: high-risk cytogenetics was defined as translocations t(4;14), t(14;16), or del (17p13) detected by FISH, or del (13q) by Q-banding according to IMWG guidelines. All others, including t(11;14), were defined as standard-risk cytogenetics. We analyzed the clinical relevance of plasma miR-92a levels with respects to CAs. Furthermore we identified miR-92a expression cut points with the most impact on outcome to investigate which of the some disease characteristics and its cut-off value had prognostic influence in MM patients. Results Chromosomal aberrations were noted in 26 (43%) MM patients after diagnosis, including 12 patients with t(4;14), 5 with t(11;14), 3 with t(14;16), 2 with del (17p13), 2 with del (13q), and 1 with t(4;14) and del (17p13), 1 with t(11;14) and del (17p13). Between MM patients with and without high-risk cytogenetics, there were no significant differences in β2-microglobulin and albumin levels (P = 0.994 and 0.85, respectively), ISS staging (P = 0.583), age (P = 0.651), sex (P = 0.585), frequency of CRAB symptoms (hypercalcemia, P = 0.755; renal insufficiency, P = 0.75; anemia, P = 0.375; bone lesion, P= 0.65, respectively). The plasma miR-92a level was significantly lower in the newly diagnosed MM with high-risk groups than in those with standard-risk groups (P = 0.015). Patients with plasma miR-92a levels < 0.04 had a significantly shorter progression-free survival (PFS) than patients with plasma miR-92a levels ≥ 0.04 (median PFS: 48 vs 15.8 months, P = 0.011). In addition, some clinical parameters were associated with adverse PFS: high-risk cytogenetics (P = 0.001), high proportions of bone marrow plasma cells (P = 0.043), high levels of serum β2-microglobulin (P = 0.022) and not attaining ≥ very good partial response (VGPR) (P = 0.007). On multivariate analysis, lower miR-92a level was an independent prognostic factor for PFS. Using the same miR-92a cut points, there was a tendency towards significant difference among standard-risk myeloma patients (P = 0.077). Moreover, the combinations of chromosomal aberrations and plasma miR-92a were able to classify newly diagnosed MM patients with three risk groups with different probabilities. Conclusion The plasma miR-92a values vary across high- and standard-risk cytogenetics in newly diagnosed MM patients. We conclude that measurement of plasma miR-92a levels may not only function as novel biomarkers for diagnosis, but may also be helpful for prognostic stratification. Disclosures: Ohyashiki: Janssen Pharmaceutical co.: Research Funding." @default.
• W2554594679 created "2016-11-30" @default.
• W2554594679 creator A5022851085 @default.
• W2554594679 creator A5023748277 @default.
• W2554594679 creator A5035670914 @default.
• W2554594679 creator A5053689963 @default.
• W2554594679 creator A5078852881 @default.
• W2554594679 date "2013-11-15" @default.
• W2554594679 modified "2023-09-27" @default.
• W2554594679 title "Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients" @default.
• W2554594679 doi "https://doi.org/10.1182/blood.v122.21.1879.1879" @default.
• W2554594679 hasPublicationYear "2013" @default.
• W2554594679 type Work @default.
• W2554594679 sameAs 2554594679 @default.
• W2554594679 citedByCount "1" @default.
• W2554594679 countsByYear W25545946792021 @default.
• W2554594679 crossrefType "journal-article" @default.
• W2554594679 hasAuthorship W2554594679A5022851085 @default.
• W2554594679 hasAuthorship W2554594679A5023748277 @default.
• W2554594679 hasAuthorship W2554594679A5035670914 @default.
• W2554594679 hasAuthorship W2554594679A5053689963 @default.
• W2554594679 hasAuthorship W2554594679A5078852881 @default.
• W2554594679 hasConcept C104317684 @default.
• W2554594679 hasConcept C126322002 @default.
• W2554594679 hasConcept C142724271 @default.
• W2554594679 hasConcept C143998085 @default.
• W2554594679 hasConcept C174475383 @default.
• W2554594679 hasConcept C2776364478 @default.
• W2554594679 hasConcept C2777542201 @default.
• W2554594679 hasConcept C2780353925 @default.
• W2554594679 hasConcept C30481170 @default.
• W2554594679 hasConcept C54355233 @default.
• W2554594679 hasConcept C71924100 @default.
• W2554594679 hasConcept C86803240 @default.
• W2554594679 hasConcept C90924648 @default.
• W2554594679 hasConceptScore W2554594679C104317684 @default.
• W2554594679 hasConceptScore W2554594679C126322002 @default.
• W2554594679 hasConceptScore W2554594679C142724271 @default.
• W2554594679 hasConceptScore W2554594679C143998085 @default.
• W2554594679 hasConceptScore W2554594679C174475383 @default.
• W2554594679 hasConceptScore W2554594679C2776364478 @default.
• W2554594679 hasConceptScore W2554594679C2777542201 @default.
• W2554594679 hasConceptScore W2554594679C2780353925 @default.
• W2554594679 hasConceptScore W2554594679C30481170 @default.
• W2554594679 hasConceptScore W2554594679C54355233 @default.
• W2554594679 hasConceptScore W2554594679C71924100 @default.
• W2554594679 hasConceptScore W2554594679C86803240 @default.
• W2554594679 hasConceptScore W2554594679C90924648 @default.
• W2554594679 hasLocation W25545946791 @default.
• W2554594679 hasOpenAccess W2554594679 @default.
• W2554594679 hasPrimaryLocation W25545946791 @default.
• W2554594679 hasRelatedWork W1975434185 @default.
• W2554594679 hasRelatedWork W2044743088 @default.
• W2554594679 hasRelatedWork W2074337512 @default.
• W2554594679 hasRelatedWork W2412912194 @default.
• W2554594679 hasRelatedWork W2470164014 @default.
• W2554594679 hasRelatedWork W2472926844 @default.
• W2554594679 hasRelatedWork W2554797011 @default.
• W2554594679 hasRelatedWork W2905101849 @default.
• W2554594679 hasRelatedWork W2999109786 @default.
• W2554594679 hasRelatedWork W3000509635 @default.
• W2554594679 hasRelatedWork W3011018027 @default.
• W2554594679 hasRelatedWork W3025322882 @default.
• W2554594679 hasRelatedWork W3028805271 @default.
• W2554594679 hasRelatedWork W3029301784 @default.
• W2554594679 hasRelatedWork W3029964619 @default.
• W2554594679 hasRelatedWork W3091877675 @default.
• W2554594679 hasRelatedWork W3110882792 @default.
• W2554594679 hasRelatedWork W3154830202 @default.
• W2554594679 hasRelatedWork W3175344527 @default.
• W2554594679 hasRelatedWork W3181675838 @default.
• W2554594679 isParatext "false" @default.
• W2554594679 isRetracted "false" @default.
• W2554594679 magId "2554594679" @default.
• W2554594679 workType "article" @default.